94-8607. National Institute of Allergy and Infectious Diseases; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Design and Screening of Protease-Resistant Synthetic Peptides With the Anti-Tumor and Immunodulating ...

[Federal Register Volume 59, Number 69 (Monday, April 11, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-8607]


[[Page Unknown]]

[Federal Register: April 11, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

National Institute of Allergy and Infectious Diseases; 
Opportunity for a Cooperative Research and Development Agreement 
(CRADA) for the Design and Screening of Protease-Resistant Synthetic 
Peptides With the Anti-Tumor and Immunodulating Activity

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases 
(NIAID) of the National Institutes of Health is seeking capability 
statements from parties interested in entering into a Cooperative 
Research and Development Agreement (CRADA) on a project to design and 
screen protease-resistant synthetic peptides with anti-tumor and 
immunomodulating activity. This project is with the Laboratory of 
Immunology (LI). The proposed project is based on NIAID's 
identification and on biochemical characterization of functionally 
important individual proteins/enzymes or surface receptors which have 
been implicated in the lymphocyte activation/differentiation or as 
having anti-tumor activity. These proteins include:
    (1) The novel set of ectoproteins (enyzmes), which are located on 
the cell surface and utilize extracellular ATP [ectoprotein 
phosphatases, ectoprotein kinases and ectoATPases as well as the 
purinergic receptors (ATP-receptor)]; and
    (2) Intracellular catalytic subunit of the cAMP-dependent protein 
kinase. The goal is to develop specific reagents (protease-resistant 
synthetic peptides and monoclonal antibody) which will either mimic the 
cytotoxic properties of ATP or will inhibit extracellular ATP-utilizing 
ecto-enyzmes. Our main efforts now are to obtain the detailed 
information (cDNA cloning, antibody production, analysis of 
transfectants) about these enzymes and receptors. The availability of 
such structural information is required for the development of new 
pharmacologically active drugs. Capability statements should include; 
(1) technical expertise of proposed Collaborator Principal Investigator 
and laboratory group in molecular cloning and antibody production, (2) 
ability of Collaborator to prepare or order highly purified synthetic 
peptides, and (3) ability to adequately contribute funding to support 
required research.

ADDRESSES: Capability statements shall be submitted to: Dr. Harold T. 
Safferstein, Technology Transfer Branch, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, Building 31, 
room 7A32, 9000 Rockville Pike, Bethesda, Maryland 20892; Tel: 301-496-
2644.

DATES: May 11, 1994.

    Dated: March 31, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-8607 Filed 4-8-94; 8:45 am]
BILLING CODE 4140-01-M